Lillian Smith - Apr 1, 2023 Form 3 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
VP, Corporate Counsel
Signature
/s/Lillian Smith
Stock symbol
ALLO
Transactions as of
Apr 1, 2023
Transactions value $
$0
Form type
3
Date filed
4/5/2023, 06:38 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
holding ALLO Common Stock 83.8K Apr 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ALLO Stock Option (Right to Buy) Apr 1, 2023 Common Stock 37.7K $13.31 Direct F2
holding ALLO Stock Option (Right to Buy) Apr 1, 2023 Common Stock 24.4K $5.04 Direct F3
holding ALLO Stock Option (Right to Buy) Apr 1, 2023 Common Stock 78.8K $4.77 Direct F4
holding ALLO Stock Option (Right to Buy) Apr 1, 2023 Common Stock 4.93K $9.69 Direct F5

Explanation of Responses:

Id Content
F1 Includes 64,366 shares of restricted stock units.
F2 1/3rd of the shares subject to the option vest on each anniversary measured from July 19th, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date
F3 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F4 25% of the shares subject to the stock option shall vest on August 27, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F5 25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.